Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery
Recent advances in metabolomic and genome mining approaches have uncovered a poorly understood metabolome that originates solely or in part from bacterial enzyme sources. Whether living on exposed surfaces or within our intestinal tract, our microbial inhabitants produce a remarkably diverse set of...
Gespeichert in:
| Veröffentlicht in: | The Journal of biological chemistry 2017-05, Vol.292 (21), p.8560-8568 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8568 |
|---|---|
| container_issue | 21 |
| container_start_page | 8560 |
| container_title | The Journal of biological chemistry |
| container_volume | 292 |
| creator | Brown, J. Mark Hazen, Stanley L. |
| description | Recent advances in metabolomic and genome mining approaches have uncovered a poorly understood metabolome that originates solely or in part from bacterial enzyme sources. Whether living on exposed surfaces or within our intestinal tract, our microbial inhabitants produce a remarkably diverse set of natural products and small molecule metabolites that can impact human health and disease. Highlighted here, the gut microbe-derived metabolite trimethylamine N-oxide has been causally linked to the development of cardiovascular diseases. Recent studies reveal drugging this pathway can inhibit atherosclerosis development in mice. Building on this example, we discuss challenges and untapped potential of targeting bacterial enzymology for improvements in human health. |
| doi_str_mv | 10.1074/jbc.R116.765388 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5448085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925820427450</els_id><sourcerecordid>28389555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-b58a0487ab65990cfe6cb13c3a6ca22d9e4907bb485a9ae46a71378d888567693</originalsourceid><addsrcrecordid>eNp1kMtKxDAUhoMoOl7W7iQv0DFpkzZxIYh4A0GQEdyFXE6nkWkzpJnBeXsjo6ILszmL_P93OB9Cp5RMKWnY-Zux02dK62lT80qIHTShRFRFxenrLpoQUtJCllwcoMNxfCP5MUn30UEpKiE55xPUznScQ_LDHIcW997GYKBwEP0aHO4haRMWPsGIU8C-X8awBtytej3gDvQidRd41gEe4D3hNoYheYi4DRG7uJpj50ebC3FzjPZavRjh5GseoZfbm9n1ffH4dPdwffVYWCZkKgwXmjDRaFNzKYltobaGVrbStdVl6SQwSRpjmOBaamC1bmjVCCeE4HVTy-oIXW65y5XpwVkYUtQLtYy-13Gjgvbq78_gOzUPa8UZE0TwDDjfArKIcYzQ_nQpUZ_KVVauPpWrrfLcOPu98if_7TgH5DYA-fB19qNG62Gw4HwEm5QL_l_4B9J2k3s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Brown, J. Mark ; Hazen, Stanley L.</creator><creatorcontrib>Brown, J. Mark ; Hazen, Stanley L.</creatorcontrib><description>Recent advances in metabolomic and genome mining approaches have uncovered a poorly understood metabolome that originates solely or in part from bacterial enzyme sources. Whether living on exposed surfaces or within our intestinal tract, our microbial inhabitants produce a remarkably diverse set of natural products and small molecule metabolites that can impact human health and disease. Highlighted here, the gut microbe-derived metabolite trimethylamine N-oxide has been causally linked to the development of cardiovascular diseases. Recent studies reveal drugging this pathway can inhibit atherosclerosis development in mice. Building on this example, we discuss challenges and untapped potential of targeting bacterial enzymology for improvements in human health.</description><identifier>ISSN: 0021-9258</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1074/jbc.R116.765388</identifier><identifier>PMID: 28389555</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; atherosclerosis ; Atherosclerosis - drug therapy ; Atherosclerosis - etiology ; Atherosclerosis - microbiology ; cardiovascular disease ; Drug Discovery ; Gastrointestinal Microbiome ; Humans ; metabolomics ; Methylamines - metabolism ; Methylamines - toxicity ; Mice ; microbiome ; Minireviews</subject><ispartof>The Journal of biological chemistry, 2017-05, Vol.292 (21), p.8560-8568</ispartof><rights>2017 © 2017 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology</rights><rights>2017 by The American Society for Biochemistry and Molecular Biology, Inc.</rights><rights>2017 by The American Society for Biochemistry and Molecular Biology, Inc. 2017 The American Society for Biochemistry and Molecular Biology, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-b58a0487ab65990cfe6cb13c3a6ca22d9e4907bb485a9ae46a71378d888567693</citedby><cites>FETCH-LOGICAL-c489t-b58a0487ab65990cfe6cb13c3a6ca22d9e4907bb485a9ae46a71378d888567693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448085/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448085/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28389555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brown, J. Mark</creatorcontrib><creatorcontrib>Hazen, Stanley L.</creatorcontrib><title>Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>Recent advances in metabolomic and genome mining approaches have uncovered a poorly understood metabolome that originates solely or in part from bacterial enzyme sources. Whether living on exposed surfaces or within our intestinal tract, our microbial inhabitants produce a remarkably diverse set of natural products and small molecule metabolites that can impact human health and disease. Highlighted here, the gut microbe-derived metabolite trimethylamine N-oxide has been causally linked to the development of cardiovascular diseases. Recent studies reveal drugging this pathway can inhibit atherosclerosis development in mice. Building on this example, we discuss challenges and untapped potential of targeting bacterial enzymology for improvements in human health.</description><subject>Animals</subject><subject>atherosclerosis</subject><subject>Atherosclerosis - drug therapy</subject><subject>Atherosclerosis - etiology</subject><subject>Atherosclerosis - microbiology</subject><subject>cardiovascular disease</subject><subject>Drug Discovery</subject><subject>Gastrointestinal Microbiome</subject><subject>Humans</subject><subject>metabolomics</subject><subject>Methylamines - metabolism</subject><subject>Methylamines - toxicity</subject><subject>Mice</subject><subject>microbiome</subject><subject>Minireviews</subject><issn>0021-9258</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtKxDAUhoMoOl7W7iQv0DFpkzZxIYh4A0GQEdyFXE6nkWkzpJnBeXsjo6ILszmL_P93OB9Cp5RMKWnY-Zux02dK62lT80qIHTShRFRFxenrLpoQUtJCllwcoMNxfCP5MUn30UEpKiE55xPUznScQ_LDHIcW997GYKBwEP0aHO4haRMWPsGIU8C-X8awBtytej3gDvQidRd41gEe4D3hNoYheYi4DRG7uJpj50ebC3FzjPZavRjh5GseoZfbm9n1ffH4dPdwffVYWCZkKgwXmjDRaFNzKYltobaGVrbStdVl6SQwSRpjmOBaamC1bmjVCCeE4HVTy-oIXW65y5XpwVkYUtQLtYy-13Gjgvbq78_gOzUPa8UZE0TwDDjfArKIcYzQ_nQpUZ_KVVauPpWrrfLcOPu98if_7TgH5DYA-fB19qNG62Gw4HwEm5QL_l_4B9J2k3s</recordid><startdate>20170526</startdate><enddate>20170526</enddate><creator>Brown, J. Mark</creator><creator>Hazen, Stanley L.</creator><general>Elsevier Inc</general><general>American Society for Biochemistry and Molecular Biology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20170526</creationdate><title>Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery</title><author>Brown, J. Mark ; Hazen, Stanley L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-b58a0487ab65990cfe6cb13c3a6ca22d9e4907bb485a9ae46a71378d888567693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>atherosclerosis</topic><topic>Atherosclerosis - drug therapy</topic><topic>Atherosclerosis - etiology</topic><topic>Atherosclerosis - microbiology</topic><topic>cardiovascular disease</topic><topic>Drug Discovery</topic><topic>Gastrointestinal Microbiome</topic><topic>Humans</topic><topic>metabolomics</topic><topic>Methylamines - metabolism</topic><topic>Methylamines - toxicity</topic><topic>Mice</topic><topic>microbiome</topic><topic>Minireviews</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brown, J. Mark</creatorcontrib><creatorcontrib>Hazen, Stanley L.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brown, J. Mark</au><au>Hazen, Stanley L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2017-05-26</date><risdate>2017</risdate><volume>292</volume><issue>21</issue><spage>8560</spage><epage>8568</epage><pages>8560-8568</pages><issn>0021-9258</issn><eissn>1083-351X</eissn><abstract>Recent advances in metabolomic and genome mining approaches have uncovered a poorly understood metabolome that originates solely or in part from bacterial enzyme sources. Whether living on exposed surfaces or within our intestinal tract, our microbial inhabitants produce a remarkably diverse set of natural products and small molecule metabolites that can impact human health and disease. Highlighted here, the gut microbe-derived metabolite trimethylamine N-oxide has been causally linked to the development of cardiovascular diseases. Recent studies reveal drugging this pathway can inhibit atherosclerosis development in mice. Building on this example, we discuss challenges and untapped potential of targeting bacterial enzymology for improvements in human health.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28389555</pmid><doi>10.1074/jbc.R116.765388</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9258 |
| ispartof | The Journal of biological chemistry, 2017-05, Vol.292 (21), p.8560-8568 |
| issn | 0021-9258 1083-351X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5448085 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals atherosclerosis Atherosclerosis - drug therapy Atherosclerosis - etiology Atherosclerosis - microbiology cardiovascular disease Drug Discovery Gastrointestinal Microbiome Humans metabolomics Methylamines - metabolism Methylamines - toxicity Mice microbiome Minireviews |
| title | Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T08%3A12%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20of%20microbe-derived%20metabolites%20to%20improve%20human%20health:%20The%20next%20frontier%20for%20drug%20discovery&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Brown,%20J.%20Mark&rft.date=2017-05-26&rft.volume=292&rft.issue=21&rft.spage=8560&rft.epage=8568&rft.pages=8560-8568&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1074/jbc.R116.765388&rft_dat=%3Cpubmed_cross%3E28389555%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28389555&rft_els_id=S0021925820427450&rfr_iscdi=true |